Killing More Cancerous Cells than Healthy at Thomas Jefferson University

Research in the laboratory of Ulrich Rodeck, MD, PhD, at Thomas Jefferson University, is looking to make prostate cancer (and other cancer types) radiation therapy safer and more effective for patients. Dr. Rodeck’s work with a new anti-cancer drug, RTA-408, currently being developed by Reata Pharmaceuticals, is directed toward protecting normal cells from radiation while enhancing the effects of radiation on cancer cells. “It was really exciting to see that combining radiation and RTA-408 more effectively inhibited tumor growth compared to using either one or the other as single treatment modalities,” said Dr. Rodeck in a news release from the university. http://prostatecancernewstoday.com/2014/11/17/killing-cancerous-cells-healthy-thomas-jefferson-university/